Print This Post
TORONTO, July 27, 2025 — While newly available anti-amyloid Alzheimer’s disease drugs have shown effectiveness in tightly controlled clinical trials, they have not been tested in real-world settings until now. Dozens of abstracts reported at AAIC 2025 showed that real world experience with the drugs lecanemab and donanemab produced comparable or better safety to large clinical trials, and patients were satisfied with the results.
Researchers tracked the drugs’ safety and effectiveness in patients from a variety of settings including U.S. clinics, memory care centers and international universities. Several of the sites are part of the Alzheimer’s Network for Treatment and Diagnostics (ALZ-NET), which was created by the Alzheimer’s Association to collect voluntary real-world data about patients receiving the new treatments, track their long-term health, and share data with scientists and clinicians.
About the Alzheimer’s Association International Conference® (AAIC®)
The Alzheimer’s Association International Conference (AAIC) is the world’s largest gathering of researchers from around the world focused on Alzheimer’s and other dementias. As a part of the Alzheimer’s Association’s research program, AAIC serves as a catalyst for generating new knowledge about dementia and fostering a vital, collegial research community.
Alzheimer’s Association: alz.org
AAIC: alz.org/aaic
AAIC newsroom: alz.org/AAICpress
AAIC 2025 hashtag: #AAIC25
About the Alzheimer’s Association®
The Alzheimer’s Association is a worldwide voluntary health organization dedicated to Alzheimer’s care, support and research. Our mission is to lead the way to end Alzheimer’s and all other dementia — by accelerating global research, driving risk reduction and early detection, and maximizing quality care and support. Our vision is a world without Alzheimer’s and all other dementia®. Visit alz.org or call +1 800.272.3900.
Dementia Researcher
